Biotechnology

A $10M investment from BVF Partners propels Entera Bio’s revolutionary oral osteoporosis drug into a pivotal Phase 3 trial, a major step for patients.

A pivotal clinical trial for PMM2-CDG, a devastating genetic disorder with no approved treatments, has completed enrollment, offering hope to thousands.

Century Health and VCU are building a massive AI-driven database to decode steatotic liver disease, a silent epidemic affecting nearly 2 billion people.

IFF targets the booming pet wellness market with PureStrong™, a probiotic built from canine science. Is this the future of dog digestive health?

A new Concord research center combines patient care and clinical trials, promising to speed up breakthroughs for complex heart, kidney, and metabolic diseases.

With promising clinical data, Clarametyx promotes key executives to accelerate its novel attack on chronic respiratory disease biofilms. Jennifer Anderson reports.

A novel triple-action topical spray for male pattern baldness enters a pivotal clinical trial, potentially disrupting a multi-billion dollar market.

Lipocine's stock plummets after its PPD drug fails a Phase 3 trial, but a promising signal in a patient subset offers a narrow path forward.

AvenCell has dosed the first patient with AVC-203, a novel allogeneic CAR-T therapy, aiming to make advanced cancer treatment more accessible and effective.

A new $3M grant program targets the immune system's role in neurodegeneration, funding bold new research to combat Alzheimer's and Parkinson's.

Scientists propose a unifying model combining 'viral mimicry' and 'cancer dark matter,' potentially revolutionizing how our immune system recognizes and fights tumors.

Tired of ineffective hair gummies? A new biotech firm backed by Khosla Ventures claims its 'pill-strength' gummy delivers real results in 30 days.

With key hires from Flatiron and Syneos, Target RWE signals major scaling plans in the booming real-world evidence market under new ownership.

Disney and Nat Geo's Earth Month campaign blends new films and park events with a 30-year, $141M conservation legacy, facing its vast environmental footprint.

As cancer strikes younger patients, a new partnership aims to find the disease before symptoms start. But is this new technology ready for prime time?

Delcath Systems is set to showcase its innovative HEPZATO KIT at SIR 2026, signaling growing adoption and a pivotal moment for its targeted cancer therapy.

With a key data readout looming for its chronic cough drug, Nocion adds a renowned dealmaker to its board, fueling speculation of a potential acquisition.

With a unique drug that preserves muscle while shedding fat, a newly fortified biotech is set to challenge the titans of the weight-loss market.

As Stryker preps its Q1 2026 report, all eyes are on whether the MedTech giant can sustain its momentum amid new products and industry-wide pressures.

In a tough biotech market, NewcelX's $1.35M financing at a 30% premium signals strong confidence in its pioneering stem cell therapy for Type 1 Diabetes.